Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma (Cell Reports Medicine, 2024)

(untitled) - Amatangelo, M; Flynt, E; Stong, N; Ray, P; Van Oekelen, O; Wang, M; Ortiz, M; Maciag, P; Peluso, T; Parekh, S; van de Donk, NWCJ; Lonial, S; et al.